| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
106,469,000 |
| Market
Cap: |
890.08(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.84 - $12.53 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 8 |
| Insider 3/6 Months : 8.6 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Arcutis Biotherapeutics is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. Co.'s product candidate, topical roflumilast cream, is used for plaque psoriasis, including intertriginous psoriasis, as well as atopic dermatitis. Co. is developing a topical foam formulation of roflumilast for the treatment of scalp psoriasis and seborrheic dermatitis; ARQ-252, a topical cream formulation of a small molecule inhibitor of Janus kinase type 1 for chronic hand eczema and vitiligo; and ARQ-255, an alternative topical formulation of ARQ-252 designed to reach into the skin in order to treat alopecia areata.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
21,052 |
101,052 |
352,515 |
| Total Buy Value |
$0 |
$199,994 |
$399,994 |
$5,409,328 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
2 |
4 |
| Total Shares Sold |
115,402 |
146,105 |
149,560 |
605,286 |
| Total Sell Value |
$1,009,930 |
$1,340,056 |
$1,355,019 |
$10,718,261 |
| Total People Sold |
5 |
5 |
5 |
11 |
| Total Sell Transactions |
8 |
14 |
16 |
59 |
| End Date |
2024-03-05 |
2023-12-03 |
2023-06-04 |
2022-06-04 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Welgus Howard G. |
Chief Medical Officer |
• – – |
2020-03-12 |
4 |
OE |
$0.58 |
$3,545 |
D/D |
6,110 |
159,992 |
|
- |
|
| Watanabe Todd Franklin |
President and CEO |
• • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
29,000 |
507,447 |
|
- |
|
| Turney Patricia A. |
Senior VP, Manufacturing |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Smither John W |
Chief Financial Officer |
• • – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
108,965 |
|
- |
|
| Welgus Howard G. |
Chief Medical Officer |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
153,882 |
|
- |
|
| Lock Kenneth A. |
Chief Commercial Officer |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Osborne David W |
Chief Technical Officer |
• – – |
2020-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
279,279 |
|
- |
|
| Schwartz Jeffrey Lawrence |
10% Owner |
– – • |
2020-02-04 |
4 |
B |
$17.00 |
$4,999,989 |
I/I |
294,117 |
3,979,292 |
1.5 |
15% |
|
| Schwartz Jeffrey Lawrence |
10% Owner |
– – • |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
I/I |
3,685,175 |
3,685,175 |
|
- |
|
| Heron Patrick J |
Director |
– • • |
2020-02-04 |
4 |
B |
$17.00 |
$8,500,000 |
I/I |
500,000 |
10,542,790 |
2.25 |
15% |
|
| Heron Patrick J |
Director |
– • • |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
I/I |
9,533,758 |
10,042,790 |
|
- |
|
| Topper James N |
10% Owner |
– – • |
2020-02-04 |
4 |
B |
$17.00 |
$8,500,000 |
D/D |
500,000 |
10,542,790 |
2.45 |
15% |
|
| Topper James N |
10% Owner |
– – • |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
9,533,758 |
10,042,790 |
|
- |
|
| Silverstein Jonathan |
Director |
– • • |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
I/I |
4,114,962 |
606,286 |
|
- |
|
| Chaudhuri Bhaskar |
Director |
– • – |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
I/I |
49,981 |
49,981 |
|
- |
|
| Chaudhuri Bhaskar |
Director |
– • – |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
37,486 |
901,391 |
|
- |
|
| Watanabe Todd Franklin |
President and CEO |
• • – |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
I/I |
49,981 |
49,981 |
|
- |
|
| Watanabe Todd Franklin |
President and CEO |
• • – |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
99,964 |
478,447 |
|
- |
|
| Osborne David W |
Chief Technical Officer |
• – – |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
24,991 |
270,279 |
|
- |
|
| Orbimed Capital Gp Vii Llc |
Director |
– • • |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
I/I |
4,114,962 |
606,286 |
|
- |
|
| Welgus Howard G. |
Chief Medical Officer |
• – – |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
I/I |
24,991 |
24,991 |
|
- |
|
| Silverstein Jonathan |
Director |
– • • |
2020-02-03 |
4 |
B |
$17.00 |
$9,501,096 |
I/I |
558,888 |
176,500 |
2.25 |
- |
|
| Orbimed Capital Gp Vii Llc |
Director |
– • • |
2020-02-03 |
4 |
B |
$17.00 |
$9,501,096 |
I/I |
558,888 |
176,500 |
2.25 |
- |
|
| Topper James N |
10% Owner |
– – • |
2020-01-30 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
509,032 |
|
- |
|
| Heron Patrick J |
Director |
– • • |
2020-01-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
509,032 |
|
- |
|
333 Records found
|
|
Page 13 of 14 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.30 (3.46%) 
